BamSEC and AlphaSense Join Forces
Learn More

BioMarin Pharmaceutical Inc. – Plans of Reorganization, Merger, Acquisition or Similar

NASDAQ: BMRN    
Share price (9/30/26): $60.00    
Market cap (9/30/26): $11.6 billion
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 144 pages ***Certain Identified Information Has Been Excluded From the Exhibit Because It Both (I) Is Not Material and (II) Is the Type That the Company Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[***]”) in This Exhibit.*** Share Purchase Agreement, Dated as of August 17, 2026, by and Among BioMarin Pharmaceutical Inc., as Purchaser, Alesta Therapeutics B.V., as the Company, Anaheim Spinco B.V., as Spinco, Each Holder of Shares Identified on Schedule 1.1(a) Hereto, as the Sellers, And, Only for the Limited Purposes Described Herein, Shareholder Representative Services LLC, as Equityholder Representative
12/34/56
EX-2.1
from 8-K 116 pages Agreement and Plan of Merger Among: Amicus Therapeutics, Inc., a Delaware Corporation; BioMarin Pharmaceutical Inc., a Delaware Corporation; Lynx Merger Sub 1, Inc., a Delaware Corporation, Dated as of December 19, 2025
12/34/56
EX-2.1
from 8-K 86 pages Agreement and Plan of Merger by and Among: Inozyme Pharma, Inc., BioMarin Pharmaceutical Inc., and Incline Merger Sub, Inc. Dated as of May 16, 2025
12/34/56
EX-2.6
from 10-K 5 pages First Amendment to the Amended and Restated Termination and Transition Agreement
12/34/56
EX-2.5
from 10-K 63 pages Termination and Transition Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. 1
12/34/56
EX-2.4
from 10-K 30 pages Termination Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. 1
12/34/56
EX-2.3
from 10-K 57 pages Amended and Restated Termination and Transition Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. 1
12/34/56
EX-2.3
from 8-K 56 pages Termination and Transition Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. - 1
12/34/56
EX-2.2
from 8-K 30 pages Termination Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. - 1
12/34/56
EX-2.1
from 8-K 55 pages Amended and Restated Termination and Transition Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. - 1
12/34/56
EX-2.1
from 8-K 44 pages Asset Purchase Agreement by and Between Biomarin Pharmaceutical Inc. and Medivation, Inc. August 21, 2015 Asset Purchase Agreement Article 1. Definitions
12/34/56
EX-2
from SC TO-C 84 pages Purchase Agreement Dated as of November 23, 2014 Among Prosensa Holding N.V., Biomarin Pharmaceutical Inc. and Biomarin Falcons B.V
12/34/56
EX-2
from 8-K 84 pages Purchase Agreement Dated as of November 23, 2014 Among Prosensa Holding N.V., Biomarin Pharmaceutical Inc. and Biomarin Falcons B.V
12/34/56
EX-2.1
from 8-K 101 pages Redacted Portions Are Indicated by [****]. Redacted Portions Filed Separately With Confidential Treatment Application. Securities Purchase Agreement by and Among: Biomarin Pharmaceutical Inc., a Delaware Corporation; Zystor Therapeutics, Inc., a Delaware Corporation; the Persons Listed on Exhibit 1.4a and George G. Arida, as the Selling Holder Representative Dated as of August 17, 2010
12/34/56
EX-2.6
from 10-K 4 pages Amendment to License Agreement
12/34/56
EX-2.5
from 10-K 4 pages Amendment to Securities Purchase Agreement
12/34/56
EX-2.4
from 10-K 8 pages Settlement Agreement and Mutual Release
12/34/56
EX-2.1
from SC 13G 1 page Statement of Control Person
12/34/56
EX-2.1
from SC 13G 1 page Statement of Control Person
12/34/56
EX-2.1
from SC 13G 1 page Statement of Control Person
12/34/56